Related by context. All words. (Click for frequent words.) 86 Patent Lawsuit 85 Patent Suit 84 Patent Ruling 83 Patent Infringement Case 83 Patent Infringement Lawsuit 83 Patent Infringement Suit 82 Settles Patent 82 Patent Suit Against 81 Wins Patent Infringement 80 Settle Patent Litigation 80 Settle Patent 79 Patent Disputes 79 Files Patent Infringement 79 Patent Suits 79 Patent Infringement Litigation 79 Patent Infringement 79 Patent Lawsuit Against 79 Patent Infringement Lawsuit Against 78 Infringes 78 Files Patent 78 Infringement Case 78 Trademark Dispute 78 Settle Patent Dispute 77 Receives Favorable Ruling 77 Settles Patent Litigation 77 Antitrust Lawsuit 77 Announce Settlement 77 Settle Litigation 77 Infringed 77 Legal Dispute 76 Patent Infringement Action 76 Patent Spat 76 Antitrust Case 76 Favorable Ruling 76 Settles Litigation 76 Wins Summary Judgment 75 Announces Favorable Ruling 75 Antitrust Suit 75 Receives Favorable 75 Preliminary Injunction Against 75 Announces Favorable 75 Settles Patent Infringement Lawsuit 74 Gets Favorable 74 Patent Infringement Suit Against 74 Patent Infringement Claim 74 Settles Patent Dispute 74 Pending Litigation 74 Injunction Against 74 Files Patent Infringement Suit 74 Shares Soar 73 Infringement Suit 73 Files Patent Infringement Lawsuit 73 Announces Dismissal 73 Antitrust Probe 73 Discontinues 73 Narrows 4Q Loss 73 Stock Soars 73 Countersuit 73 Ups Ante 73 Settles Dispute 73 Settle Dispute Over 72 Nasdaq Delisting 72 Posts Wider Loss 72 Settle Dispute 72 Patent Infringement Claims 72 Licensing Pact 72 Files Countersuit Against 72 Wins Dismissal 72 Shareholder Suits 72 Stock Plunges 72 Trademark Lawsuit 72 Wins Approval 72 Reach Settlement 72 Settles Charges 72 Terminate Agreement 72 Shares Plummet 72 Arthritis Drug 72 Narrows Loss 72 Seeks Injunction 71 Suit Vs 71 Posts 1Q Profit 71 Gets Favorable Ruling 71 Denies Motion 71 Outlines Strategy 71 Q1 Loss Widens 71 Unveils Newest 71 Shares Surge 71 Files Motion 71 Refocuses 71 Receives Notification 71 Cuts Costs 71 Patent Reexamination 71 4Q Profit Soars 71 Wins Injunction 71 Posts 4Q Profit 71 Trademark Infringement Lawsuit 71 Receives Patent 71 Settles Suit 71 Plans Job Cuts 71 Suit Filed 71 Vigorously Defend 71 Suit Settled 70 Patent Upheld 70 Restate Results 70 Rehear 70 Initiates Patent Infringement 70 Court Invalidates 70 Judge Nixes 70 Hostile Bid 70 Files Lawsuits 70 Clears Path 70 3Q Profit Plunges 70 Announce License Agreement 70 Settlement Reached 70 Antitrust Settlement 70 Lawsuit Settled 70 Reduces Debt 70 Reaches Settlement Agreement 70 Denies Bid 70 Trims Loss 70 Beats Expectations 70 CFO Resigns 70 Complaint Against 70 Settles Lawsuits 70 Completes Tender Offer 70 Shares Tumble 70 Shares Climb 70 3Q Loss Widens 70 Plans Buyback 70 Resolves Dispute 70 Shares Slump 70 Court Reverses 70 Files Suit 70 Lawsuit Dismissed 70 Shareholder Suit 70 Patent Validity 70 Q4 Profit Plunges 70 Stock Tumbles 70 Restate Financials 70 Settles Patent Suit 70 Posts Loss 70 Contract Dispute 70 Announces Job Cuts 70 Court Dismisses 70 Files Patent Application 70 Settle Antitrust 70 1Q Loss Widens 70 Shareholder Lawsuits 70 Resolve Dispute 70 Judge Tosses Out 70 Starts Shipping 70 Shareholder Lawsuit 70 1Q Loss Narrows 69 Licensing Deal 69 Profit Slips 69 Commercializes 69 Jury Verdict 69 Merger Talks 69 Signs License Agreement 69 False Advertising 69 Sign License Agreement 69 Patent Infringement Lawsuits 69 Posts 4Q Loss 69 Profit Soars 69 4Q Loss Widens 69 Announces Licensing Agreement 69 4Q Profit Falls 69 Chip Makers 69 FCC Approves 69 Trademark Suit 69 Ruling Upheld 69 Finalize Agreement 69 Sell Itself 69 Tops Forecasts 69 Reaches Settlement 69 Takeover Speculation 69 Discrimination Case 69 Proxy Fight 69 Licenses Patents 69 Antitrust Complaint 69 Antitrust Ruling 69 Lowers Forecast 69 Profit Dips 69 Files Complaint 69 Countersues 69 Announces Immediate Availability 69 Profits Soar 69 Receives Subpoena 69 Acacia Subsidiary 69 Profit Beats Estimates 69 Ups Bid 69 Files Antitrust Suit 69 Achieves Milestone 69 Faces Suit 69 Buyout Talks 69 Settle Lawsuit 69 Restates Earnings 69 Boosts Outlook 69 Awarded Patent 69 Gains Ground 69 iPhone Exclusivity 69 Files Petition 69 Raises Bid 69 Gets Subpoena 69 Q4 Loss Narrows 69 Claim Against 69 Profits Drop 69 Derivative Lawsuit 69 Net Loss Widens 69 Expands Scope 69 Reports Wider Loss 69 Settles Fraud 69 1Q Profit Falls 69 Sign Licensing Agreement 69 Expand Relationship 69 Patent Litigation 69 3Q Profit Falls 69 Patents Upheld 69 Ups Guidance 69 Exec Says 69 Settle Lawsuits 69 Seeks Approval 69 Significantly Increases 69 Quadruples 69 4Q Profit Surges 68 Q4 Profit Drops 68 3Q Profit Jumps 68 Posts Profit 68 Posts 2Q Profit 68 Action Suit Against 68 Seeks Damages 68 Dismiss Lawsuit 68 Case Settled 68 Nears Deal 68 Faces Lawsuit 68 3Q Profit Down 68 Losses Widen 68 Appeals Court Upholds 68 Earnings Soar 68 Cross Licensing Agreement 68 Forges Ahead 68 Shareholders Reject 68 Amplifies 68 Losses Narrow 68 Exec Sees 68 Board Authorizes 68 Announces FDA Clearance 68 Q3 Loss Widens 68 Expand Collaboration 68 Files Lawsuit 68 Announce Licensing Agreement 68 Patent Issued 68 2Q Profit 68 Q2 Loss Narrows 68 Legal Tussle 68 Withdraws Offer 68 RealMoney Radio Mailbag 68 Begins Shipment 68 Maker Sues 68 Abandons Bid 68 Posts Strong 68 Abandons Plans 68 Analyst Predicts 68 Profit Plunges 68 Profits Plunge 68 FDA Panel Recommends 68 Profit Doubles 68 FTC Clears 68 Outlook Disappoints 68 Vioxx Suits 68 Posts 2Q Loss 68 Reaffirms Outlook 68 1Q Profit Down 68 Q2 Loss Widens 68 Lowers Outlook 68 Posts 2Q 68 2Q Loss Widens 68 FDA Clears 68 Judge Tosses 68 Complaint Filed 68 Signs Licensing Agreement 68 3Q Profit Drops 68 Earnings Cheat Sheet 68 Boosts Forecast 68 Loss Widens 68 Drags Down 68 Backdating Case 68 Upholds Ruling 68 Can Proceed 68 Successfully Completes Tender Offer 68 Acquire Assets 68 4Q Profit Dips 68 Q4 Loss Widens 68 Antitrust Suit Against 68 Lowers Guidance 68 Settles Lawsuit 68 Stockholders Approve Merger 68 Beats Views 68 Quarterly Loss Widens 68 Settle Suit 68 3Q Profit Surges 68 Reaches Tentative Settlement 68 Chalks Up 68 Biotech Firm 68 Profit Beats Expectations 68 Court Throws Out 68 Extends Tender Offer 68 4Q Profit Jumps 68 2Q Loss 68 Nearly Triples 68 Achieves Significant 68 Q3 Loss Narrows 68 Withdraws Application 68 Profit Misses Estimates 68 Suit Dismissed 68 Court Hears Arguments 68 Suit Against 68 Boosts Productivity 68 Collaborates With 68 Extend Partnership 68 Beats Forecast 68 Q1 Profit Soars 68 Request Denied 68 Buyout Rumors 68 Spins Off 68 Amend Merger Agreement 68 Submits Application 67 Confirms Validity 67 Remains Committed 67 Q2 Profit Soars 67 Posts Smaller 67 License Pact 67 Blood Thinner 67 Terminate Merger Agreement 67 1Q Profit 67 3Q Profit Up 67 2Q Profit Up 67 Halts Production 67 Successfully Defends 67 Speeds Up 67 Slashes Price 67 1Q Loss 67 Net Loss Narrows 67 Files Patent Suit 67 Q2 Profit Plunges 67 Permanent Injunction Against 67 Announces Discontinuation 67 Unsolicited Proposal From 67 Fee Dispute 67 Lawsuit Involving 67 Court Overturns 67 Outsells 67 4Q Profit Down 67 Introduces Next Generation 67 Boosts Dividend 67 Lawsuit Brought 67 Accounting Errors 67 Loss Narrows 67 Expands Portfolio 67 Posts 1Q 67 Lawsuits Filed 67 Lays Groundwork 67 Nears Settlement 67 Announces Definitive Agreement 67 Raises Outlook 67 Lung Cancer Drug 67 Applauds FCC 67 Broadens Scope 67 2Q Profit Soars 67 Lowers Price 67 Buyout Bid 67 Unveils Next Generation 67 Q4 Profit Surges 67 Begins Shipping 67 Beats Forecasts 67 Sees Profit 67 Loses Lawsuit 67 Extends Collaboration 67 Rejects Appeal 67 Wider Loss 67 Complies With 67 Slashes Outlook 67 Hikes Dividend 67 Posts 3Q Profit 67 Terminates Merger Agreement 67 Makes Strides 67 Cholesterol Drug 67 Stock Plummets 67 Analyst Downgrade 67 Reaches Pact 67 Settle Lawsuit Over 67 Files IND 67 Reverses Loss 67 Q1 Loss Narrows 67 Gets Approval 67 2Q Loss Narrows 67 4Q Profit Up 67 Shares Plunge 67 Cuts Forecast 67 4Q Profit Slips 67 3Q Profit Rises 67 Dismiss Case 67 Q3 Profit Jumps 67 Update# 67 Issues Statement Regarding 67 Prevails 67 Patent Covering 67 Infringe 67 Case Dismissed 67 Delivers Next Generation 67 Q3 Profit Soars 67 1Q Profit Rises 67 Announces Proposed Settlement 67 Withdraws Proposal 67 Sharpens Focus 67 Judge Clears Way 67 Posts Solid 67 Slashes Prices 67 Settles Claim 67 2Q Profit Drops 67 Trademark Infringement 67 Receives Positive 67 Loss Shrinks 67 Profits Rise 67 2Q Profit Down 67 Ruling Favors 67 Verdict Upheld 67 Purported Class 67 1Q Profit Slips 67 Drops Suit 67 Device Maker 67 Slashes Guidance 67 Inks Licensing Deal 67 Q2 Adj 67 Announces Stockholder Approval 67 Streamlines Operations 67 Develop Next Generation 67 Unveils Revolutionary 67 Action Suit 67 Reduces Size 67 Raises Forecast 67 Court Dismisses Lawsuit 67 Q2 Profit Surges 67 Approve Merger 67 Strikes Deal 67 Faces Setback 67 Files Suit Against 67 3Q Profit Soars 66 Sweetens Bid 66 2Q Profit Falls 66 Appeals Upholds 66 Pending Acquisition 66 Reach Settlement Agreement 66 Board Unanimously Rejects 66 Drug Fails 66 Offers Glimpse 66 Rejects Bid 66 Appeal Ruling 66 Toshiba Develops 66 Posts 4Q 66 DVD Copying 66 Q3 Profit Drops 66 4Q Profit Drops 66 Ruling Expected 66 Formalizes 66 Spins Out 66 Extends Offer 66 Files Trademark 66 1Q Profit Up 66 Hits Milestone 66 Coughs Up 66 Investigates Claims 66 Found Liable 66 Reconfirms 66 Inequitable Conduct 66 2nd Qtr Profit 66 Doubles Capacity 66 Discrimination Suit 66 Epilepsy Drug 66 Posts Wider 4Q Loss 66 Buyback Plan 66 Halts Sale 66 Receives Milestone Payment 66 Results Disappoint 66 Pushes Ahead 66 Tops Estimates 66 Seeks Buyer 66 Announces License Agreement 66 Analyst Upgrade 66 Cranks Up 66 4Q Profit Rises 66 Gets Reprieve 66 Issued Patent 66 Share Buybacks 66 Suits Against 66 Legal Woes 66 Osteoporosis Drug 66 Patent Infringements 66 Tops Expectations 66 Seeks Dismissal Of 66 Faces Delisting 66 Supreme Court Hears 66 Raises Guidance 66 Provides Guidance 66 Shareholder Sues 66 Delays Filing 66 Jointly Develop 66 ONN.tv Report 66 Refreshes 66 Suit Alleges 66 4Q Loss 66 Q2 Profit Drops 66 2Q Profit Climbs 66 Debuts Next Generation 66 3Q Profit 66 Defends Itself 66 Takeover Talk 66 Delays Ruling 66 Raises Dividend 66 Q1 Adj 66 Settle Shareholder 66 Q1 Profit Jumps 66 Q1 Profit Declines 66 Sex Discrimination Case 66 Considers Sale 66 Sales Surpass 66 Drops Sharply 66 Taro Receives 66 Wins Injunction Against 66 Earnings Disappoint 66 Antitrust Violations 66 Reaches Agreement 66 Shareholders Approve Merger 66 Hangs Tough 66 Unveils Expanded 66 Judge Throws Out 66 Introduces Enhanced 66 Receives FDA Clearance 66 2Q Profit Surges 66 Quarterly Profit Rises 66 Nasdaq Delisting Notice 66 Receives Clearance 66 Underperforms 66 Announce Early Termination 66 Remains Neutral 66 Malpractice Suit 66 Q2 Profit Plummets 66 Launches Generic Version 66 Case Thrown Out 66 Discrimination Lawsuit 66 Declaratory Judgment 66 Boosts Buyback 66 Confirms Receipt 66 Profit Exceeds Estimates 66 Boosts Profit 66 Sets Aside 66 Completes Purchase Of 66 Acacia Subsidiary Enters 66 Delay Filing 66 Validates 66 Q2 Profit Declines 66 Quarterly Loss 66 Premarket Movers 66 Momentum Continues 66 Loses Bid 66 Fraud Suit 66 Lawsuit Settlement 66 Misses Expectations 66 Expects 1Q 66 Bumps Up 66 Loses Appeal Against 66 Demonstrates Commitment 66 Unsolicited Tender Offer 66 Asset Swap 66 Teva Provides Update 66 Announce Collaboration Agreement 66 Settles Dispute With 66 Misses Estimates 66 Shifts Gears 66 Outbids 66 Announce Expiration 66 Hear Arguments 66 Scoops Up 66 Fine Tunes 66 Trial Halted 66 Restates Results 66 Ekes Out 66 Complete Merger 66 Q4 Profit Declines 66 Misses Views 66 Posts 3Q 66 Lawsuit Filed Over 66 More Than Doubles 66 Phasing Out 66 Extends Commitment 66 Leans Toward 66 Sign Definitive Agreement 66 Profit Quadruples 66 Surpasses Expectations 66 Lawsuit Against 66 Quarterly Profit Drops 66 Penetrates 66 Fortifies 66 Extend Relationship 66 Settle Trademark 66 Completes Enrollment 66 Secures Patent 66 Profit Sinks 66 Resolves Litigation 65 Pushes Back 65 Settle Suits 65 Court Tosses 65 Q3 Adj 65 Fourth Quarter Profit Drops 65 Remains Confident 65 Posts Narrower Loss 65 HSR Waiting Period 65 4th Qtr Loss 65 Migraine Drug 65 Bulks Up 65 Profit Misses 65 Extends Leadership 65 1Q Profits 65 Moves Towards 65 Anounces 65 Copyright Infringement Lawsuit 65 Develop Innovative 65 Trial Nears 65 Mulls Options 65 Injunctive Relief 65 Higher Than Expected 65 Terminates Contract 65 Q1 Profit Drops 65 Vacates 65 OKs Buyback 65 Strengthens Balance Sheet 65 Momentum Builds 65 Amends Agreement 65 Profit Jumps 65 Updates Guidance 65 Battle Heats Up 65 Provides Update Regarding 65 Court Upholds Ruling 65 Stockholders Approve Acquisition 65 Investigates Possible 65 Jury Sides 65 Suit Claims 65 Judge Refuses 65 Q3 Profit Plunges 65 Non Infringement 65 Q3 Profit Surges 65 Sees Continued 65 Clears Way 65 Slims Down 65 Spears Conservatorship 65 Buyout Offer 65 Fitz Bits 65 Antitrust Approval 65 Beat Expectations 65 Slowing Growth 65 Generic Version 65 Earnings Decline 65 Sees 2Q Profit 65 Sets Precedent 65 Files Claim 65 Narrower Loss 65 Licenses Novel 65 Suit Seeks 65 Court Nixes 65 Second Quarter Profit Rises 65 Gets Mixed Reviews 65 Counter Sues 65 Shows Promise 65 Inks License 65 Beat Estimates 65 Lawsuit Filed Against 65 Profits Decline 65 Proves Successful 65 Rejects Request 65 2Q Profit Slides 65 2Q Profit Jumps 65 Settle Differences 65 Upholds 65 Provides Status 65 Recall Issued 65 Finalizes Acquisition 65 Ups Dividend 65 Wider Than Expected 65 Q4 Profit Soars 65 Reaffirms Commitment 65 Snaps Up 65 Restructures Debt 65 Announces Termination 65 1Q Profit Soars 65 Unlocks 65 Announce Availability 65 Firm Sues 65 Profit Tops Estimates 65 Completes Transaction 65 Enters Into Settlement Agreement 65 3Q Loss 65 Lawsuit Filed 65 Extend Collaboration 65 Approves Settlement 65 Receives Approvable Letter 65 Mad Money Mailbag 65 Beats Estimates 65 Profit Triples 65 Shareholder Claims 65 Hires Lobbyist 65 Meets Estimates 65 Profit Drops 65 Lawsuit Alleges 65 Copyright Infringement Case 65 Reports 4Q Loss 65 Age Bias 65 STRATEGY ANALYTICS 65 Confirms Commitment 65 Posts Quarterly 65 Restate Earnings 65 Stock Buyback 65 Matches Expectations 65 Exec Resigns 65 Submits NDA 65 Explores Options 65 Profit Tumbles 65 Attorneys Fees 65 Aquires 65 Generic Versions 65 3Q Profit Climbs 65 Exec Testifies 65 Proxy Contest 65 Completes Patient Enrollment 65 Judge Hears Arguments 65 Agreement Reached 65 2Q Profit Doubles 65 Gets Upgraded 65 Completes Divestiture 65 3Q Loss Narrows 65 Expands Availability 65 Raise Stake 65 KB Home Swings 65 Antitrust Clearance 65 Shareholder Investigation 65 Strengthens Position 65 2Q Profit Rises 65 Q3 Profit Declines 65 Profits Jump 65 Latest Addition 65 Suits Filed 65 Meets Expectations 65 Makes Unsolicited Bid 65 Q1 Profit Dips 65 1Q Profit Surges 65 Gets Bigger 65 Settles Suits 65 1Q Profit Drops 65 Patents Covering 65 Regains Compliance 65 Jointly Offer 65 Introduces Innovative 65 Third Quarter Profit Rises 65 Optimistic Outlook 65 Hiring Spree 65 Buyout Deal 65 Feds Seek 65 Whistleblower Suit 65 Ink Deal 65 Hits Snag 65 Completes Merger 65 Case Involving 65 Lawsuit Dismissal 65 FDA Okays 65 Files Complaint Against 65 Judge Overturns 65 Extends Reach 65 Approves Merger 65 Gets Clearance 65 Dramatically Expands 65 Moves Ahead 65 Postpones Annual Meeting 65 Announces Early Termination 65 Not Liable 65 2Q Profits 65 Jointly Announce 65 Mulling Bid 65 Squares Off 65 Earns Milestone Payment 65 Antitrust Lawsuit Against 65 Obtains Exclusive Rights 65 Holders Approve 65 Could Trigger 65 Unveils Innovative 65 RealMoney Radio Recap 65 No. #-# Fed. 65 Files Lawsuit Against 65 Revenues Decline 65 Waiting Period 65 Settle Fraud 65 Exceeds Estimates 65 Announces Successful Completion 65 Gobbles Up 65 Backs FY# Outlook 65 3Q Profits 65 Delayed Again 65 Be Bought 65 Receives Notice 65 Pulls Down 65 Gets FDA Clearance 65 Equity Stake 65 1Q Profit Declines 65 Spying Case 65 Distribution Pact 65 3Q Profit Dips 65 Downsizes 65 Overturns 65 Denies Petition 65 Judge Upholds 65 Completes Reorganization 65 Awarded Patents 65 Posts Better Than 65 Makes Headway 65 Issues Resolved 64 Files Antitrust Lawsuit 64 Receives Unsolicited 64 Sexual Harassment Case 64 Court Vacates 64 Boosts Profits 64 Develop Novel 64 Develops Innovative 64 Awarded Damages 64 Settle Suit Over 64 Directors Authorizes 64 Announce Agreement 64 Consummates 64 4Q Profit Slides 64 Hits Roadblock 64 Court Reverses Ruling 64 Navigates 64 Mulls Sale 64 Receives Notice From 64 Posts Narrower 64 Boosts Quarterly Dividend 64 Unwraps 64 Appeal Denied 64 Options Backdating 64 Revises Guidance 64 Announces Tentative Approval 64 Judge Declares Mistrial 64 Jumps Higher 64 Gains Traction 64 Panel Backs 64 Boost Profits 64 4Q Loss Narrows 64 Achieves Record Sales 64 Seeks Delay 64 Deals Blow 64 Finds Itself 64 Sells Itself 64 Posts Lower 64 Enters Joint Venture 64 Q1 Profit Plunges 64 Delays Filing Annual Report 64 Extends Warranty 64 Takeover Talks 64 Sees Profits 64 Rehearing 64 4Q Profit 64 Posts 3Q Loss 64 Seeks Dismissal 64 Loses Appeal 64 Milestone Payment 64 Urges Rejection 64 Announce Receipt 64 Filed Against 64 More Than Doubled 64 Strengthens Its 64 4Q Profit Plunges 64 Reaches Settlement With 64 Stockholders Reject 64 Enters Agreement 64 Court Clears Way 64 Million Verdict 64 Denies Allegations 64 Regains Compliance With 64 Inks Pact 64 Completes Transition 64 Court Upholds 64 1Q Profit Jumps 64 Tosses Out 64 Explore Strategic Alternatives 64 Neutral Analyst Blog 64 Tops Views 64 Receives Confirmation 64 Reaffirms FY# Outlook 64 Offers Unprecedented 64 Dramatically Increases 64 Pomerantz Law Firm 64 Breaks Barriers 64 Eliminates Need 64 Completes Sale Of 64 Keeps Growing 64 Guides Inline 64 Lawyer Quits 64 Profit Fell 64 Dramatically Reduces 64 Share Repurchases 64 Receives Funding 64 Seeks Injunction Against 64 Enemy Combatant Case 64 Share Buyback 64 Issues Recall 64 Rheumatoid Arthritis Drug 64 Receives Orphan Drug Designation 64 Remains Optimistic 64 Sells Stake 64 Enters Strategic 64 Blood Pressure Drug 64 Revenue Climbs 64 Faces Uphill Battle 64 Restates 64 Regains Full 64 2Q Profit Dips 64 Obtains License 64 Ban Upheld 64 Q4 Profit Jumps 64 Shareholders Approve 64 Brain Damaged Woman 64 Profit Declines 64 Update8 64 Faces Possible 64 Lifts Dividend 64 Price Hikes 64 Expand Scope 64 Decision Delayed 64 Justices Weigh 64 Significantly Reduces 64 Q2 Profit Rises 64 Could Revolutionize 64 Settles Suit Over 64 Further Strengthens 64 Files Voluntary 64 Seek Damages 64 Settle Probe 64 Successfully Concludes 64 Realigns 64 Delivers Faster 64 Profits Climb 64 Sees Positive 64 Loses Ground 64 Purchases Moore Microprocessor 64 Lupus Drug 64 File Suit 64 Successfully Completed 64 Profit Climbs 64 Settles Patent Lawsuit 64 Suffers Setback 64 Has Spiked 64 Beefs Up 64 Broadens 64 Exploring Strategic Alternatives 64 Profit Plummets 64 Cholesterol Lowering Drug 64 Q1 Profit Slips 64 Dismisses Claims 64 Up Sharply 64 Receives Tentative Approval 64 Rises Sharply 64 Gout Drug 64 Liquidates 64 Piracy Lawsuits 64 Gets Thumbs Down 64 Deal Collapses 64 Narrows Guidance 64 Retools 64 Questions Loom 64 Anemia Drugs 64 Reaches Deal 64 Suit Accuses 64 Widely Used 64 Awaits Decision 64 Resubmit 64 Seek Shareholder Approval 64 Releases Statement Regarding 64 Drug Maker 64 Ruling Delayed 64 Being Studied 64 Significantly Improves 64 Earnings Scorecard 64 ANADIGICS Announces 64 Reorganizes 64 Formally Launches 64 Lowers Expectations 64 Midday Trading 64 Sees Upside 64 Q2 Profit Climbs 64 Announce Merger 64 Third Quarter Loss Widens 64 Execs Face